Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)
42.89
-1.22 (-2.77%)
Mar 19, 2026, 3:00 PM CST
SHA:600211 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,982 | 2,800 | 3,128 | 2,545 | 2,127 |
Other Revenue | - | 6.73 | 6.24 | 9.69 | 12.06 |
| 2,982 | 2,807 | 3,134 | 2,555 | 2,139 | |
Revenue Growth (YoY) | 6.23% | -10.45% | 22.69% | 19.45% | 55.75% |
Cost of Revenue | 172.47 | 162.1 | 158.67 | 204.74 | 225.8 |
Gross Profit | 2,809 | 2,645 | 2,976 | 2,350 | 1,913 |
Selling, General & Admin | 1,774 | 1,685 | 1,881 | 1,541 | 1,254 |
Research & Development | 74.08 | 28.94 | 17.35 | 88.13 | 60.86 |
Other Operating Expenses | -8.47 | 37.1 | 38.17 | 32.54 | 26.2 |
Operating Expenses | 1,839 | 1,751 | 1,937 | 1,662 | 1,340 |
Operating Income | 969.91 | 893.44 | 1,039 | 688.27 | 572.75 |
Interest Expense | - | -9.48 | -11.59 | -14.36 | -4.33 |
Interest & Investment Income | 7.48 | 74.38 | 86.22 | 21.35 | 2.67 |
Currency Exchange Gain (Loss) | - | -2.47 | -0.11 | -3.83 | -4.78 |
Other Non Operating Income (Expenses) | 66.3 | -0.17 | -0.47 | -0.39 | -0.35 |
EBT Excluding Unusual Items | 1,044 | 955.69 | 1,113 | 691.03 | 565.96 |
Gain (Loss) on Sale of Investments | 1.66 | -18.99 | -210.53 | -14.17 | 146.47 |
Gain (Loss) on Sale of Assets | 0.11 | 1.9 | 0.34 | -0.23 | -0.17 |
Asset Writedown | -4.85 | - | -190.38 | -218.62 | -458.06 |
Other Unusual Items | - | 213.48 | 186.03 | 5.36 | 0.64 |
Pretax Income | 1,041 | 1,152 | 898.19 | 463.39 | 254.85 |
Income Tax Expense | 123.64 | 95.01 | 87.95 | 88.08 | 41.82 |
Earnings From Continuing Operations | 916.98 | 1,057 | 810.24 | 375.31 | 213.03 |
Minority Interest in Earnings | 20.95 | -5.79 | -9.33 | -5.47 | -4.09 |
Net Income | 937.93 | 1,051 | 800.91 | 369.84 | 208.94 |
Net Income to Common | 937.93 | 1,051 | 800.91 | 369.84 | 208.94 |
Net Income Growth | -10.78% | 31.26% | 116.56% | 77.01% | -50.03% |
Shares Outstanding (Basic) | 322 | 322 | 323 | 323 | 323 |
Shares Outstanding (Diluted) | 322 | 322 | 323 | 323 | 323 |
Shares Change (YoY) | -0.05% | -0.14% | 0.09% | -0.21% | 0.53% |
EPS (Basic) | 2.91 | 3.26 | 2.48 | 1.15 | 0.65 |
EPS (Diluted) | 2.91 | 3.26 | 2.48 | 1.15 | 0.65 |
EPS Growth | -10.74% | 31.45% | 116.37% | 77.38% | -50.29% |
Free Cash Flow | 988.79 | 957.19 | 1,042 | 735.41 | -59.05 |
Free Cash Flow Per Share | 3.07 | 2.97 | 3.23 | 2.28 | -0.18 |
Dividend Per Share | - | 1.957 | 1.492 | 0.574 | 0.260 |
Dividend Growth | - | 31.21% | 159.93% | 120.69% | -33.72% |
Gross Margin | 94.22% | 94.23% | 94.94% | 91.98% | 89.44% |
Operating Margin | 32.53% | 31.83% | 33.14% | 26.94% | 26.78% |
Profit Margin | 31.46% | 37.46% | 25.55% | 14.48% | 9.77% |
Free Cash Flow Margin | 33.16% | 34.10% | 33.24% | 28.79% | -2.76% |
EBITDA | 1,049 | 967.64 | 1,107 | 757.52 | 654.2 |
EBITDA Margin | 35.20% | 34.48% | 35.31% | 29.65% | 30.59% |
D&A For EBITDA | 79.55 | 74.2 | 68.05 | 69.24 | 81.45 |
EBIT | 969.91 | 893.44 | 1,039 | 688.27 | 572.75 |
EBIT Margin | 32.53% | 31.83% | 33.14% | 26.94% | 26.78% |
Effective Tax Rate | 11.88% | 8.25% | 9.79% | 19.01% | 16.41% |
Revenue as Reported | - | - | - | 2,555 | 2,139 |
Advertising Expenses | - | 6.23 | 2.22 | 0.05 | 0.24 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.